Incyte Quinoline KRAS Inhibitor Patent Publication, Apr 15, 2026
Summary
The EPO published patent application EP4415824A1 by Incyte Corporation on April 15, 2026, titled 'Quinoline Compounds as Inhibitors of KRAS.' The application covers quinoline derivatives as KRAS G12C inhibitors for cancer treatment, with 21 named inventors and IPC classifications spanning C07D 471/04, A61K 31/437, and A61P 35/00. The application is designated in all 31 EPC contracting states including Germany, France, the United Kingdom, and Italy. Pharmaceutical companies developing targeted oncology therapies should review this publication for freedom-to-operate considerations, noting that publication of the application does not yet confer granted protection and Incyte's claims remain pending.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 51 changes logged to date.
What changed
The EPO published patent application EP4415824A1 for Incyte Corporation, covering quinoline compounds as KRAS inhibitors (IPC: C07D 471/04; A61K 31/437). The application names 21 inventors and designates all 31 EPC contracting states. Publication of the application makes the claims publicly available for opposition and observation purposes.
Pharmaceutical companies engaged in targeted oncology drug development, particularly KRAS G12C inhibitor programs, should conduct freedom-to-operate analysis against this published application. While the patent is not yet granted, publication begins the 18-month publication period during which third parties may file observations. Incyte's published claims in the quinoline space may be relevant to competitors developing related small-molecule oncology candidates.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
Publication EP4415824A1 Kind: A1 Apr 15, 2026
Applicants
Incyte Corporation
Inventors
YE, Qinda, MCCAMMANT, Matthew, POLICARPO, Rocco, SHVARTSBART, Artem, ZHU, Wenyu, ROACH, Jeremy, HOANG, Gia, HU, Bin, LI, Gencheng, SUSICK, Robert, POLAM, Padmaja, ZHANG, Fenglei, QI, Chao, WANG, Xiaozhao, YAO, Wenqing, SOKOLSKY, Alexander, YIN, Haolin, ZHAO, Le, CARLSEN, Peter
IPC Classifications
A61P 35/00 20060101AFI20230503BHEP C07D 471/04 20060101ALI20230503BHEP A61K 31/437 20060101ALI20230503BHEP A61K 31/4545 20060101ALI20230503BHEP A61K 31/4745 20060101ALI20230503BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.